Observations placeholder
Lexiva
Identifier
024015
Type of Spiritual Experience
Number of hallucinations: 4
Background
A description of the experience
Fosamprenavir (marketed under the trade names Lexiva in the U.S. and Telzir in Europe) is a drug for the treatment of HIV infections. It is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003, while the EMA approved it on July 12, 2004. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir.
Most common Lexiva side effects
- Rashes - (94 reports)
- Diarrhea - (85 reports)
- Drug exposure during pregnancy - (83 reports)
- Nausea - (75 reports)
- Fatigue - (54 reports)
- Nausea and vomiting - (51 reports)
- Abortion spontaneous - (43 reports)
- Headache - (42 reports)
- Fever - (38 reports)
- Dizziness - (33 reports)